HomeCompareBMY vs EV

BMY vs EV: Dividend Comparison 2026

BMY yields 4.17% · EV yields 1.99%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BMY wins by $97.9K in total portfolio value
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
EV
EV
● Live price
1.99%
Share price
$21.85
Annual div
$0.44
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.6K
Annual income
$226.73
Full EV calculator →

Portfolio growth — BMY vs EV

📍 BMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYEV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + EV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
EV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
EV
Annual income on $10K today (after 15% tax)
$169.42/yr
After 10yr DRIP, annual income (after tax)
$192.72/yr
At 15% tax rate, BMY beats the other by $33,657.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + EV for your $10,000?

BMY: 50%EV: 50%
100% EV50/50100% BMY
Portfolio after 10yr
$71.6K
Annual income
$20,025.20/yr
Blended yield
27.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BMY right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
EV
Analyst Ratings
4
Buy
14
Hold
2
Sell
Consensus: Hold
Price Target
$13.50
-38.2% upside vs current
Range: $12.00 — $15.00
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
EV buys
0
No recent congressional trades found for BMY or EV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYEV
Forward yield4.17%1.99%
Annual dividend / share$2.49$0.44
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%0%
Portfolio after 10y$120.5K$22.6K
Annual income after 10y$39,823.66$226.73
Total dividends collected$91.0K$2.1K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldHold
Analyst price target$62.73$13.50

Year-by-year: BMY vs EV ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrEV PortfolioEV Income/yrGap
1← crossover$11,271$571.12$10,899$199.31+$372.00BMY
2$12,884$824.20$11,865$203.03+$1.0KBMY
3$14,993$1,206.32$12,902$206.56+$2.1KBMY
4$17,839$1,797.27$14,016$209.92+$3.8KBMY
5$21,826$2,738.11$15,210$213.11+$6.6KBMY
6$27,643$4,289.31$16,491$216.14+$11.2KBMY
7$36,534$6,955.64$17,864$219.01+$18.7KBMY
8$50,861$11,770.13$19,336$221.73+$31.5KBMY
9$75,402$20,980.23$20,914$224.30+$54.5KBMY
10$120,504$39,823.66$22,605$226.73+$97.9KBMY

BMY vs EV: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

EVStock

The fund will invest at least 80% of its assets in companies that derive at least 50% of its revenue from the battery recycling and production business and/or devotes at least 50% of its assets to the battery recycling and production business. The fund is non-diversified.

Full EV Calculator →
📬

Get this BMY vs EV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.